Uncategorized

In which patients or for what conditions would you consider recommending re-esterified omega-3s as first-line therapy for treating ocular surface disease?

by  • 

PointI am a big believer that proper functioning of the lids and meibomian glands is critical for managing ocular surface disease (OSD). When examining an OSD patient, I pay particular attention to the eyelid margin and look at the expressibility and quality of the meibum and the overall tear quality. I find that MGD is present in the majority of dry eye patients; however, it is often overlooked and underemphasized in most treatment protocols. To that end, for all of my OSD patients I have them start warm compresses with (Read more...)

Uncategorized

Rocket 4 researcher describes trial results comparing Rhopressa with timolol

by  • 

The once-daily glaucoma eye drop Rhopressa was found to be comparable to twice-daily timolol in lowering IOP, according to 90-day results of Aerie Pharmaceuticals’ Rocket 4 phase 3 trial.Three-month data from 214 patients using Rhopressa (netarsudil ophthalmic solution 0.02%) and 209 patients using timolol also revealed that Rhopressa met non-inferiority criteria when compared with timolol for prespecified baseline IOPs less than 27 mm Hg and less than 28 mm Hg.

Read more →

Uncategorized

‘Pop and chop’ yields shorter case times for residents than ‘divide and conquer’ technique

by  • 

Residents who used a “pop and chop” technique during cataract surgery were more efficient and their patients had similar complication rates compared to when a “divide and conquer” technique was used, according to a study.In most residency training programs, the divide and conquer technique is taught as the initial method of nucleofractis. However, a pop and chop technique offered shorter case times and produced similar visual outcomes for patients when performed by residents, Fredric J. Gross, MD, told Ocular Surgery News.

Read more →